SALMONELLA

Volver

Resultados 61 resultados LastUpdate Última actualización 18/01/2019 [19:22:00] pdf PDF




Solicitudes publicadas en los últimos 90 días / Applications published in the last 90 days



Página1 de 3 nextPage   Mostrar por página


ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF

NºPublicación: WO2019014398A1 17/01/2019

Solicitante:
ACTYM THERAPEUTICS INC [US]

Resumen de: WO2019014398A1

Provided are immunostimulatory bacteria and pharmaceutical compositions containing the bacteria. The immunostimulatory bacteria provided herein contain one or more modalities that enhance the anti-tumor activity of the immunostimulatory bacteria. Among the immunostimulatory bacteria provided are bacteria, such as Salmonella species, which are modified to be auxotrophic or are auxotrophic for adenosine and/or contain plasmids encoding RNAi, such as shRNA and micro RNA, that mediate gene disruption and/or expression of immune checkpoints, such as TREX1, VISTA, PD-L1 and, genes that influence the immune system. The bacteria contain additional modifications to enhance their anti -tumor activity. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the pharmaceutical compositions.



traducir


 

Virulence Attenuated Bacteria For Treatment Of Malignant Solid Tumors

NºPublicación: US2019015497A1 17/01/2019

Solicitante:
UNIV BASEL [CH]

Resumen de: US2019015497A1

The present invention relates to recombinant virulence attenuated Gram-negative bacterial strains for use in a method of treating a malignant solid tumor in a subject.



traducir


 

Proteins and nucleic acids useful in vaccines targeting Klebsiella Pneumoniae

NºPublicación: US2019015496A1 17/01/2019

Solicitante:
EVAXION BIOTECH APS [DK]

Resumen de: US2019015496A1

The present invention relates to proteins and nucleic acids derived from Klebsiella pneumonia as well as therapeutic and diagnostic uses of the proteins and nucleic acids.



traducir


 

ENGINEERED IMMUNOSTIMULATORY BACTERIAL STRAINS AND USES THEREOF

NºPublicación: US2019017050A1 17/01/2019

Solicitante:
ACTYM THERAPEUTICS INC [US]

Resumen de: US2019017050A1

Provided are immunostimulatory bacteria and pharmaceutical compositions containing the bacteria. The immunostimulatory bacteria provided herein contain one or more modalities that enhance the anti-tumor activity of the immunostimulatory bacteria. Among the immunostimulatory bacteria provided are bacteria, such as Salmonella species, which are modified to be auxotrophic or are auxotrophic for adenosine and/or contain plasmids encoding RNAi, such as shRNA and microRNA, that mediate gene disruption and/or expression of immune checkpoints, such as TREX1, VISTA, PD-L1 and, genes that influence the immune system. The bacteria contain additional modifications to enhance their anti-tumor activity. Also provided are methods of inhibiting the growth or reducing the volume of a solid tumor by administering the pharmaceutical compositions.



traducir


 

BIOCONJUGATES MADE FROM RECOMBINANT N-GLYCOSYLATED PROTEINS FROM PROCARYOTIC CELLS

NºPublicación: EP3427749A1 16/01/2019

Solicitante:
GLAXOSMITHKLINE BIOLOGICALS SA [BE]

Resumen de: EP3427749A1

The present invention is directed to a bioconjugate vaccine such as an O1-bioconjugate vaccine, comprising: a protein carrier comprising an inserted consensus sequence, D/E - X - N - Z - S/T, wherein X and Z may be any natural amino acid except proline; and at least one antigenic polysaccharide from at least one bacterium, linked to the protein carrier, wherein the at least one antigenic polysaccharide is a bacterial O-antigen from one or more strain of Shigella, E. coli or Pseudomonas aeruginosa; and, optionally, an adjuvant. In another aspect of the present invention is directed to a method of producing a O1- bioconjugate in a bioreactor comprising a number of steps.



traducir


 

VACCINE FOR PREVENTION OF NECROTIC ENTERITIS IN POULTRY

NºPublicación: WO2019010135A1 10/01/2019

Solicitante:
UNIV ARIZONA STATE [US]

Resumen de: WO2019010135A1

In certain embodiments, the present invention provides a poultry vaccine comprising an antigenic protein comprising a PlcC protein unit that is operably linked to a peptide linker that is operably linked to a NetB protein unit., where the vaccine is effective in stimulating a protective cellular and/or humoral immune response to C. perfringens. Methods are also provided for making the vaccine and for vaccinating poultry by administering such a vaccine.



traducir


 

Polysaccharide Purification for Vaccine Production using Lytic Enzymes, Tangential Flow Filtration, and Multimode Chromatography

NºPublicación: US2019010187A1 10/01/2019

Solicitante:
INVENTPRISE LLC [US]

Resumen de: US2019010187A1

An improved, cost effective and shortened process of purification of the capsular polysaccharide of S. Pneumoniae, Group B Streptococcus, H. Influenzae, S. Typhoid and N. meningitidis is disclosed. The process includes a cocktail of enzyme treatment, tangential flow filtration, and multimodal chromatography purification. For Gram-negative bacteria, endotoxin removal process involves endotrap HD resin. This shortened process achieved the purity required by WHO/EP/BP for the use in human vaccine preparation, with simple steps and higher yield as compared to conventional processes. The steps of the process avoid use of organic solvents such as, for example, alcohol, phenol, and ultracentrifugation that are otherwise expensive and time consuming to perform, and/or health hazards for commercial use. This process disclosed is also simple, efficient, non-toxic, easy to scale-up, and environmentally friendly.



traducir


 

DNA VACCINE FOR USE IN PANCREATIC CANCER PATIENTS

NºPublicación: US2019008936A1 10/01/2019

Solicitante:
VAXIMM AG [CH]

Resumen de: US2019008936A1

The present invention relates to an attenuated mutant strain of Salmonella comprising a recombinant DNA molecule encoding a VEGF receptor protein. In particular, the present invention relate to the use of said attenuated mutant strain of Salmonella in cancer immunotherapy.



traducir


 

POLYSACCHARIDE PURIFICATION FOR VACCINE PRODUCTION USING LYTIC ENZYMES, TANGENTIAL FLOW FILTRATION, AND MULTIMODE CHROMATOGRAPHY

NºPublicación: WO2019010080A1 10/01/2019

Solicitante:
INVENTPRISE LLC [US]

Resumen de: WO2019010080A1

An improved, cost effective and shortened process of purification of the capsular polysaccharide of S. Pneumoniae, Group B Streptococcus, H. Influenzae, S, Typhoid and N. meningitidis is disclosed. The process includes a cocktail of enzyme treatment, tangential flow filtration, and multimodal chromatography purification. For Gram-negative bacteria, endotoxin removal process involves endotrap HD resin. This shortened process achieved the purity required by WHO/EP/BP for the use in human vaccine preparation, with simple steps and higher yield as compared to conventional processes. The steps of the process avoid use of organic solvents such as, for example, alcohol, phenol, and ultracentrifugation that are otherwise expensive and time consuming to perform, and/or health hazards for commercial use. This process disclosed is also simple, efficient, non-toxic, easy to scale-up, and environmentally friendly.



traducir


 

Combined enteropathogen recombinant construct

NºPublicación: US2019008979A1 10/01/2019

Solicitante:
GUERRY PATRICIA [US]
MONTEIRO MARIO ARTUR [CA]
SAVARINO STEPHEN [US]

Resumen de: US2019008979A1

The inventive subject matter relates to a construct comprising antigens derived from multiple enterobacteria including Campylobacter jejuni capsule polysaccharide polymer, enterotoxigenic Escherichia coli recombinant polypeptide construct and lipopolysaccharide from Shigella spp. The subject invention also relates to a method of inducing an immune response utilizing the inventive composition.



traducir


 

Process for the production of a DNA vaccine for cancer immunotherapy

NºPublicación: AU2017295004A1 03/01/2019

Solicitante:
VAXIMM AG

Resumen de: AU2017295004A1

The present invention relates to a method for producing a DNA vaccine for cancer immunotherapy comprising at least the steps of (a) transforming an attenuated strain of Salmonella with at least one DNA molecule comprising at least one expression cassette encoding at least one antigen or at least one fragment thereof; (b) characterizing at least one transformed cell clone obtained in step (a); and (c) selecting at least one of the transformed cell clone(s) characterized in step (b) and further characterizing said at least one selected transformed cell clone. The present invention further relates to a DNA vaccine obtainable by the method according to the present invention.



traducir


 

DENDROBIUM OFFICINALE ENDOPHYTIC FUNGI STRAIN AND EXTRACELLULAR POLYSACCHARIDE PRODUCED THEREBY AS WELL AS EXTRACTION METHOD AND APPLICATION OF EXTRACELLULAR POLYSACCHARIDE

NºPublicación: WO2019000850A1 03/01/2019

Solicitante:
UNIV SOUTH CHINA TECH [CN]

Resumen de: WO2019000850A1

The present invention provides a dendrobium officinale endophytic fungi strain and an extracellular polysaccharide produced thereby as well as an extraction method and application of the extracellular polysaccharide. The extraction process for the extracellular polysaccharide comprises: activating a strain; culturing a seed liquid; fermenting and culturing; filtering the fermented liquid in vacuum; concentrating the filtered liquid in vacuum; carrying out alcohol precipitation on the concentrated liquid; precipitating and centrifuging; dialyzing after dissolving the precipitates with water; freezing and drying the dialyzed liquid in vacuum; and obtaining the extracellular polysaccharide. The dendrobium officinale endophytic fungi strain belongs to the fusarium solani, and the xtracellular polysaccharide produced thereby has an inhibition effect to Escherichia coli, staphylococcus aureus, salmonella, and bacillus subtilis.



traducir


 

BACTERIAL CELLS WITH IMPROVED TOLERANCE TO POLYAMINES

NºPublicación: US2019002935A1 03/01/2019

Solicitante:
DANMARKS TEKNISKE UNIV [DK]

Resumen de: US2019002935A1

Provided are bacterial cells genetically modified to improve their tolerance to certain commodity chemicals, such as polyamines, and methods of preparing and using such bacterial cells for production of polyamines and other compounds.



traducir


 

ALTERING MICROBIAL POPULATIONS & MODIFYING MICROBIOTA

NºPublicación: WO2019002218A2 03/01/2019

Solicitante:
SNIPR TECH LIMITED [GB]

Resumen de: WO2019002218A2

The invention relates to guided nucleases, CRISPR/Cas systems, crRNAs, single gRNAs, vectors, methods and pharniaceutical compositions, for example for targeting sporulating bacteria, or for targeting C difficile, Salmonella, E coli or Streptococcus.



traducir


 

PROCESS

NºPublicación: JP2018538415A 27/12/2018

Solicitante:
\u30B0\u30E9\u30AF\u30BD\u30B9\u30DF\u30B9\u30AF\u30E9\u30A4\u30F3 \u30D0\u30A4\u30AA\u30ED\u30B8\u30AB\u30EB\u30BA \u30BD\u30B7\u30A8\u30C6 \u30A2\u30CE\u30CB\u30E0

Resumen de: WO2017109733A2

A method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells is provided, said method comprising a step of extracting LPS from the gram negative bacterial cell in a LPS extraction solution comprising a salt, water, an alcohol, and a further organic solvent. Compositions and uses of the extracted LPS are also provided.



traducir


 

Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

NºPublicación: AU2017260323A1 20/12/2018

Solicitante:
UNIV ARKANSAS
TEXAS A & M UNIV SYS

Resumen de: AU2017260323A1

Vaccine compositions including a yeast comprising an immunostimulatory polypeptide and optionally an antigenic polypeptide are provided herein. The immunostimulatory polypeptide and the antigenic polypeptide are expressed or displayed on the surface of the yeast vaccine composition. Methods of using the vaccine composition to vaccinate subjects are also provided.



traducir


 

PRODUCTION OF ROUGH-TYPE SALMONELLA ENTERITIDIS AND THE GENETIC MODIFICATIONS THEREOF FOR USE AS AN AVIAN VACCINE

NºPublicación: WO2018231078A2 20/12/2018

Solicitante:
FARM VETERINARIOS SAC [PE]

Resumen de: WO2018231078A2

The present invention relates to a strain of Salmonella enteritidis 3934vac from which the waaL gene has been deleted in order to obtain a rough phenotype (3934vac DwaaL), as well as to the method for obtaining same and to the oligos used, with a view to reducing toxicity and maintaining immunogenicity for the use of same as a vaccine. The present invention also relates to a strain of Salmonella enteritidis 3934vac DwaaL, i.e. of the rough type, which has been modified to express the fibre gene of type-1 avian adenovirus, as well as to the method for obtaining a strain of Salmonella enteritidis 3034 vac DwaaL which expresses a fibre gene of Ava-I. The invention further comprises the development of a novel avian vaccine against the AvA-I virus, which is live, recombinant, effective and harmless and which was developed using a process involving inserting and integrating AVa-I fibre genes into the chromosome of a non-pathogenic attenuated strain of Salmonella enteritidis bacteria.



traducir


 

PREPARATION OF LIVE VACCINES

NºPublicación: EP3415643A1 19/12/2018

Solicitante:
LOHMANN ANIMAL HEALTH GMBH [DE]

Resumen de: EP3415643A1

Described is a method for the generation of a live vaccine containing stable bacteria carrying at least three attenuating mutations and a vaccine containing bacteria obtained by said method.



traducir


 

Compositions

NºPublicación: US2018353600A1 13/12/2018

Solicitante:
INSTITUTE FOR RES IN BIO MEDICINE [CH]

Resumen de: US2018353600A1

Compositions capable of enhancing and/or eliciting an immune response in a subject and methods of using the compositions. The compositions are capable of enhancing an IgA immune response and/or an IgG immune response and comprise an agent capable of reducing the level of binding of ATP to a P2X7 receptor to a subject. The compositions are for oral administration.



traducir


 

Manufacture of Vaccines and Compositions for the Prevention of Salmonella Infections

NºPublicación: US2018353590A1 13/12/2018

Solicitante:
BHARAT BIOTECH INTERNATIONAL LTD [IN]

Resumen de: US2018353590A1

Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.



traducir


 

MITRECIN A POLYPEPTIDE WITH ANTIMICROBIAL ACTIVITY

NºPublicación: US2018353576A1 13/12/2018

Solicitante:
MITRE CORP [US]

Resumen de: US2018353576A1

The present invention provides a Mitrecin A polypeptide useful in prevention and treatment of one or more bacteria. Also provided is a method to kill or prevent growth of one or more bacteria comprising contacting the one or more bacteria with a Mitrecin A polypeptide. The target bacteria can be selected from the group consisting of a Gram-positive bacterium, a Gram-negative bacterium, or both. In one embodiment, the present invention is drawn to a polynucleotide encoding a Mitrecin A polypeptide, a vector comprising the polynucleotide, a host cell comprising the polynucleotide, or a composition comprising the Mitrecin A polypeptide, the polynucleotide, the vector, or the host cell.



traducir


 

CELL-PENETRATING BACTERIAL E3-UBIQITIN-LIGASES FOR USE IN IMMUNOTHERAPY

NºPublicación: AU2018267685A1 13/12/2018

Solicitante:
WESTFAELISCHE WILHELMS UNIV MUENSTER

Resumen de: AU2018267685A1

Abstract The present invention relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bac-teria of the genus Salmonella or Shigella and variants, fragments and immunmodulatory domains thereof, for use in immunotherapy. The present invention further relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bacteria of the genus Salmonella or Shigella and variants, fragments and immunmodulatory domains thereof, for delivering cargo molecules into eukaryotic cells.



traducir


 

Vaccines and Compositions for the Prevention of Salmonella Infections

NºPublicación: US2018353589A1 13/12/2018

Solicitante:
BHARAT BIOTECH INTERNATIONAL LTD [IN]

Resumen de: US2018353589A1

Disclosed are stable conjugate vaccine formulations for protection against Salmonella typhi, and methods of conjugation between Vi-polysaccharide of S. typhi to tetanus toxoid as the carrier protein, responsible for producing improved T-dependent immune response against Typhoid fever caused by Salmonella typhi. The methods disclosed in this invention and the resulting formulations are capable of inducing immunity against typhoid fever including in children below 2 years of age, through only a single injection to comprise a complete vaccination schedule.



traducir


 

GnRH STF2 GnRH inserted STF2 recombinant protein and uses thereof

NºPublicación: KR20180130217A 07/12/2018

Solicitante:
\uAC74\uAD6D\uB300\uD559\uAD50 \uC0B0\uD559\uD611\uB825\uB2E8

Resumen de: KR20180130217A

본 발명은 GnRH(gonadotropin-releasing hormone)가 삽입된 STF2(salmonella typhimurium flagellin fljB) 재조합 단백질 및 이의 용도에 관한 것으로, 보다 구체적으로 STF2 재조합 단백질 제조용 유전자 카세트를 이용하여 12개의 GnRH가 STF2 N 말단 단편 및 C 말단 단편 내부에 링커로 연결되어 삽입된 STF2 재조합 단백질을 암호화하는 유전자를 포함하는 발현 벡터, 상기 발현 벡터로 형질전환된 숙주세포, 상기 숙주세포를 배양하는 단계를 포함하는 GnRH가 삽입된 STF2 재조합 단백질의 제조 방법, 및 상기 제조 방법으로 제조된 GnRH가 삽입된 STF2 재조합 단백질 및 이를 포함하는 백신 조성물에 관한 것이다.



traducir


 

USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER

Nº publicación: US2018344823A1 06/12/2018

Solicitante:
CLEVELAND BIOLABS INC [US]

Resumen de: US2018344823A1

The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.


traducir



 

Página1 de 3 nextPage Mostrar por página

Volver